T. Maughan

Geraint T. Williams, G. Williams, S. Roberts, 1999, Journal of gastrointestinal surgery : official journal of the Society for Surgery of the Alimentary Tract.

Combined modality treatment in oesophageal carcinoma.

T. Crosby, T. Maughan, 1998, Clinical oncology (Royal College of Radiologists (Great Britain)).

Comprehensive pharmacogenetic profiling of the epidermal growth factor receptor pathway for biomarkers of response to, and toxicity from, cetuximab

S. Tejpar, J. Maynard, J. Cheadle, 2017, Journal of Medical Genetics.

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

Aung Ko Win, I. Deary, M. Nöthen, 2019, Nature Communications.

Personalised Medicine: The Promise, the Hype and the Pitfalls

T. Maughan, K. Gaitskell, T. Feiler, 2017, The New bioethics : a multidisciplinary journal of biotechnology and the body.

Combining Oncolytic Adenovirus with Radiation—A Paradigm for the Future of Radiosensitization

L. Seymour, K. Fisher, T. Maughan, 2017, Front. Oncol..

Pathological grading of regression following neoadjuvant chemoradiation therapy: the clinical need is now

Ricky A. Sharma, T. Maughan, T. MacGregor, 2012, Journal of Clinical Pathology.

Cetuximab therapy in first-line metastatic colorectal cancer and intermittent palliative chemotherapy: review of the COIN trial

H. Wasan, G. Griffiths, T. Maughan, 2008, Expert review of anticancer therapy.

Spend less to achieve more: Economic analysis of intermittent versus continuous cetuximab in KRAS wild-type patients with metastatic colorectal cancer.

P. Dunne, M. Lawler, H. Wasan, 2022, Journal of cancer policy.

Addition of panitumumab to irinotecan: Results of PICCOLO, a randomized controlled trial in advanced colorectal cancer (aCRC).

T. Hickish, S. Gwyther, P. Quirke, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Intermittent chemotherapy (CT) plus continuous or intermittent cetuximab (C) in the first-line treatment of advanced colorectal cancer (aCRC): Results of the two-arm phase II randomized MRC COIN-B trial.

R. Butler, H. Wasan, T. Maughan, 2011, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Molecular subtype-specific efficacy of anti-EGFR therapy in colorectal cancer is dependent on the chemotherapy backbone

C. Punt, L. Vermeulen, P. Quirke, 2021, British Journal of Cancer.

Oxaliplatin/capecitabine vs oxaliplatin/infusional 5-FU in advanced colorectal cancer: the MRC COIN trial

H. Wasan, R. Kaplan, T. Maughan, 2012, British Journal of Cancer.

Role for Nucleotide Excision Repair Gene Variants in Oxaliplatin-Induced Peripheral Neuropathy.

M. Wagner, H. McLeod, D. Fisher, 2018, JCO precision oncology.

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract

M. Highley, J. Graham, L. Wall, 2016, BMC Research Notes.

Prognosis of patients with peritoneal metastatic colorectal cancer given systemic therapy: an analysis of individual patient data from prospective randomised trials from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

C. Tournigand, D. Sargent, C. Punt, 2016, The Lancet. Oncology.

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as first-line therapy for advanced colorectal cancer.

D. Rea, D. Richel, C. Punt, 2005, Annals of oncology : official journal of the European Society for Medical Oncology.

Colorectal cancer in the adjuvant setting: perspectives on treatment and the role of prognostic factors.

R. Labianca, M. Ychou, S. Cascinu, 2003, Annals of oncology : official journal of the European Society for Medical Oncology.

RANDOMIZED TRIAL OF THREE CHEMOTHERAPY REGIMENS FOR ADVANCED COLORECTAL CANCER

D. Kerr, J. Berlin, R. Stephens, 2002 .

Efficacy of anti-epidermal growth factor receptor agents in patients with RAS wild-type metastatic colorectal cancer ≥ 70 years.

C. Bokemeyer, E. Van Cutsem, H. Lenz, 2022, European journal of cancer.

X-ACT: an important step on an unfinished journey.

T. Maughan, 2012, Annals of oncology : official journal of the European Society for Medical Oncology.

A phase 1 trial of the safety, tolerability and biological effects of intravenous Enadenotucirev, a novel oncolytic virus, in combination with chemoradiotherapy in locally advanced rectal cancer (CEDAR)

K. Fisher, T. Maughan, D. Sebag‐Montefiore, 2020, Radiation Oncology.

Derived neutrophil to lymphocyte ratio as a prognostic factor in patients with advanced colorectal cancer according to RAS and BRAF status: a post-hoc analysis of the MRC COIN study

J. Bridgewater, T. Maughan, D. Fisher, 2017, Anti-cancer drugs.

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.

Dual inhibition of epidermal growth factor and insulin-like 1 growth factor receptors reduce intestinal adenoma burden in the Apcmin/+ mouse

A. Clarke, T. Maughan, P. Shaw, 2011, British Journal of Cancer.

Figitumumab in patients with refractory metastatic colorectal cancer previously treated with standard therapies: a nonrandomized, open-label, phase II trial

R. Salazar, J. Cassidy, S. Green, 2014, Cancer Chemotherapy and Pharmacology.

6LBA Addition of cetuximab to oxaliplatin-based combination chemotherapy (CT) in patients with KRAS wild-type advanced colorectal cancer (ACRC): a randomised superiority trial (MRC COIN)

J. Cheadle, T. Maughan, D. Fisher, 2009 .

Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer: analysis from 2530 patients in randomised clinical trials

P. Quirke, J. Cheadle, G. Middleton, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Introducing the Cancer Research UK Advanced Radiotherapy Technologies Network (ART-NET).

M. V. van Herk, K. Harrington, R. Mackay, 2017, Clinical oncology (Royal College of Radiologists (Great Britain)).

Strengthening clinical cancer research in the United Kingdom

R. B. Hamilton, M. Parmar, D. Stewart, 2011, British Journal of Cancer.

Buparlisib with thoracic radiotherapy and its effect on tumour hypoxia: A phase I study in patients with advanced non-small cell lung carcinoma

F. Gleeson, R. Muschel, W. Mckenna, 2019, European journal of cancer.

Mitomycin or cisplatin chemoradiation with or without maintenance chemotherapy for treatment of squamous-cell carcinoma of the anus (ACT II): a randomised, phase 3, open-label, 2 × 2 factorial trial.

J. Ledermann, R. James, D. Cunningham, 2013, The Lancet. Oncology.

A new opportunity for radiotherapy research in the UK.

T. Maughan, 2009, Clinical oncology (Royal College of Radiologists (Great Britain)).

Patient-reported outcomes during and after definitive chemoradiotherapy for oesophageal cancer

C. Hurt, D. Cunningham, J. Bridgewater, 2015, British Journal of Cancer.

Long-term results of a randomised trial of involved field radiotherapy vs extended field radiotherapy in stage I and II Hodgkin lymphoma.

P. Hoskin, D. Linch, T. Maughan, 2005, Clinical oncology (Royal College of Radiologists (Great Britain)).

Functional Parameters Derived from Magnetic Resonance Imaging Reflect Vascular Morphology in Preclinical Tumors and in Human Liver Metastases

Warren W. Kretzschmar, J. Schnabel, B. Irving, 2018, Clinical Cancer Research.

5-fluorouracil and folinic acid-induced mucositis: no effect of oral glutamine supplementation.

Sarah E. Jebb, M. Elia, S. Jebb, 1994, British Journal of Cancer.

Adjuvant chemotherapy for colorectal cancer

T. Maughan, 2001, British Journal of Cancer.

NRF2 metagene signature is a novel prognostic biomarker in colorectal cancer.

Chieh-Hsi Wu, C. Holmes, T. Maughan, 2019, Cancer genetics.

NEOSCOPE: A randomised phase II study of induction chemotherapy followed by oxaliplatin/capecitabine or carboplatin/paclitaxel based pre-operative chemoradiation for resectable oesophageal adenocarcinoma

H. Grabsch, C. Hurt, Ricky A. Sharma, 2017, European journal of cancer.

Laparoscopic Cholecystectomy: Incidental Carcinoma of the Gallbladder with Abdominal Wall and Axillary Node Metastasis

K. Horgan, M. Wheeler, T. Maughan, 1997, HPB surgery : a world journal of hepatic, pancreatic and biliary surgery.

Comprehensive analysis of colorectal cancer-risk loci and survival outcome: A prognostic role for CDH1 variants.

R. Houlston, P. Law, V. Escott-Price, 2019, European journal of cancer.

Clinicopathological and molecular characteristics of RSPO fusion-positive colorectal cancer

Y. Yatabe, S. Leedham, R. Hamamoto, 2022, British Journal of Cancer.

CA125inovarian tumourtissue atsecond laparotomy

B. Jasani, G. Williams, M. Shelley, 1989 .

Genetic variation in ST6GAL1 is a determinant of capecitabine and oxaliplatin induced hand‐foot syndrome

D. Kerr, R. Houlston, V. Escott-Price, 2022, International journal of cancer.

Antigen CA125 in tumor tissue and serum from patients with adenocarcinoma of the ovary.

B. Jasani, G. Williams, M. Shelley, 1988, Gynecologic oncology.

This is a repository copy of Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B

D. Sargent, C. Bokemeyer, J. Marshall, 2019 .

BRAF and NRAS Locus-Specific Variants Have Different Outcomes on Survival to Colorectal Cancer

V. Escott-Price, J. Cheadle, R. Kaplan, 2016, Clinical Cancer Research.

FOCUS4: MAMS Trial Design in Action. Early Closure of FOCUS4-D (Pan-HER 1, 2 and 3 Inhibitor Versus Placebo) in Advanced Colorectal Cancer (aCRC) Patients, with Tumours Wildtype (WT) for KRAS, NRAS, BRAF and PIK3CA

R. Butler, P. Quirke, H. Wasan, 2017 .

24 Phase III study of gemcitabine (Gemzar®) versus best supportive care (BSC) in advanced non-small cell lung cancer (NSCLC)

J. Carmichael, M. Nicolson, N. Thatcher, 1997 .

Intermittent chemotherapy plus either intermittent or continuous cetuximab for first-line treatment of patients with KRAS wild-type advanced colorectal cancer (COIN-B): a randomised phase 2 trial

R. Butler, H. Wasan, G. Middleton, 2014, The Lancet. Oncology.

Dynamic and adaptive cancer stem cell population admixture in colorectal neoplasia

P. Wirapati, P. Dunne, L. Trusolino, 2022, Cell stem cell.

Genome-wide asociation study and meta-analysis in Northrn European populations replicate multiple colorectal cancer risk

Johanna, François G. Meyer, Ripatti, 2017 .

The Challenge of Combining Chemo- and Radiotherapy with Checkpoint Kinase Inhibitors

T. Humphrey, T. Maughan, Samuel C. Durley, 2020, Clinical Cancer Research.

Preclinical testing of an Atr inhibitor demonstrates improved response to standard therapies for esophageal cancer

E. Hammond, K. Leszczynska, T. Maughan, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

A Systematic Review of Health Economic Evaluations of Proton Beam Therapy for Adult Cancer: Appraising Methodology and Quality Clinical and Translational Radiation Oncology

F. V. Heuvel, A. Gray, T. Maughan, 2019 .

Study protocol: a multi-centre randomised study of induction chemotherapy followed by capecitabine ± nelfinavir with high- or standard-dose radiotherapy for locally advanced pancreatic cancer (SCALOP-2)

C. Hurt, E. O’Neill, J. Bridgewater, 2019, BMC Cancer.

ARCII: A phase II trial of the HIV protease inhibitor Nelfinavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer

James M. Wilson, E. O’Neill, M. Partridge, 2016, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Phase II trial ARCII: A phase II trial of the HIV protease inhibitor Nelﬁnavir in combination with chemoradiation for locally advanced inoperable pancreatic cancer Radiotherapy and Oncology

James M. Wilson, E. O’Neill, M. Partridge, 2016 .

The attitudes of 1066 patients with cancer towards participation in randomised clinical trials

D. Farewell, V. Farewell, T. Maughan, 2010, British Journal of Cancer.

Effects of impaired renal function on the pharmacokinetics of raltitrexed (Tomudex ZD1694).

P. Beale, P. Hoskin, I. Judson, 1998, British Journal of Cancer.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

C. Hurt, P. Quirke, G. Griffiths, 2018, British Journal of Cancer.

BRAF V600E Mutation in First-line Metastatic Colorectal Cancer: an Analysis of Individual Patient Data from the ARCAD Database.

C. Bokemeyer, E. Van Cutsem, H. Lenz, 2021, Journal of the National Cancer Institute.

Long-term results and recurrence patterns from SCOPE-1: a phase II/III randomised trial of definitive chemoradiotherapy +/− cetuximab in oesophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2017, British Journal of Cancer.

15LBA Intermittent versus continuous oxaliplatin-based combination chemotherapy in patients with advanced colorectal cancer: a randomised non-inferiority trial (MRC COIN)

J. Cassidy, T. Maughan, D. Fisher, 2009 .

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).

J. Desai, E. Van Cutsem, J. Tabernero, 2021 .

Preoperative radiation and irinotecan in combination with 5 fluorouracil (5-FU) and low-dose leucovorin (LV) in locally advanced rectal cancer (LARC)

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2005 .

Preliminary phase II SOCRATES study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Phase II study of carboplatin and adriamycin as second line chemotherapy in small cell lung cancer.

N. Bleehen, R. Osborne, T. Maughan, 1993, Clinical oncology (Royal College of Radiologists (Great Britain)).

A phase I/II and pharmacokinetic study of irinotecan in combination with capecitabine as ﬁrst-line therapy for advanced colorectal cancer

D. Kerr, D. Richel, G. Groenewegen, 2005 .

Comprehensive pharmacogenetic profiling of advanced colorectal cancer.

J. Maynard, J. Cheadle, S. Idziaszczyk, 2013 .

Long-term results and recurrence patterns from SCALOP: a phase II randomised trial of gemcitabine- or capecitabine-based chemoradiation for locally advanced pancreatic cancer

R. Abrams, C. Hurt, J. Staffurth, 2017, British Journal of Cancer.

R. Abrams, C. Hurt, J. Staffurth, 2015, International journal of radiation oncology, biology, physics.

Management of the asymptomatic primary in the palliative treatment of metastatic colorectal cancer

D. Clements, T. Maughan, R. Adams, 2009, Colorectal disease : the official journal of the Association of Coloproctology of Great Britain and Ireland.

The use of a chelating derivative of alpha melanocyte stimulating hormone for the clinical imaging of malignant melanoma.

T. Maughan, C. G. Knight, D. Bard, 1992, The British journal of radiology.

Continuous vs intermittant chemotherapy for advanced colorectal cancer: preliminary results of the MRC cr06b randomised trial

D. Kerr, C. McArdle, R. Stephens, 2001 .

The hard road to data interpretation: 3 or 6 months of adjuvant chemotherapy for patients with stage III colon cancer?

R. Labianca, J. Meyerhardt, M. Buyse, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Efficacy, tolerability and management of raltitrexed (Tomudex) monotherapy in patients with advanced colorectal cancer. a review of phase II/III trials.

R. James, S. Clarke, J. Zalcberg, 2002, European journal of cancer.

Preliminary results of a multicentre randomised trial comparing 3 chemotherapy regimens (De Gramont, Lokich and Raltitrexed) in metastatic colorectal cancer.

D. Kerr, C. McArdle, R. Stephens, 1999 .

Cetuximab Is Contraindicated in the Perioperative Treatment of Colorectal Liver Metastases.

T. Hickish, O. Garden, D. Cunningham, 2015, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Long term results and patterns of recurrence from SCOPE 1: A phase II/III randomised trial of definitive chemoradiotherapy (dCRT) plus or minus cetuximab (dCRT plus C) in esophageal cancer

C. Hurt, D. Cunningham, J. Staffurth, 2016 .

Patterns of progression, treatment of progressive disease, and postprogression survival in the new EPOC study.

O. Garden, D. Cunningham, J. Bridgewater, 2014 .

The economic burden of colorectal cancer across Europe: a population-based cost-of-illness study.

M. Coleman, M. Lawler, T. Maughan, 2021, The lancet. Gastroenterology & hepatology.

The combination of multiple doses of etanidazole and pimonidazole in 48 patients: a toxicity and pharmacokinetic study.

N. Bleehen, P. Workman, T. Maughan, 1991, Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology.

Abnormal clinical pharmacokinetics of the developmental radiosensitizers pimonidazole (Ro 03-8799) and etanidazole (SR 2508).

N. Bleehen, P. Workman, T. Maughan, 1990, International journal of radiation oncology, biology, physics.

A multiple dose study of the combined radiosensitizers Ro 03-8799 (pimonidazole) and SR 2508 (etanidazole).

N. Bleehen, P. Workman, T. Maughan, 1989, International journal of radiation oncology, biology, physics.

Excess treatment related deaths and impaired quality of life show raltitrexed is inferior to infusional 5FU regimens in the palliative chemotherapy of advanced colorectal cancer (CRC): Final results of MRC CR06

D. Kerr, C. McArdle, R. Stephens, 2000 .

Socrates phase II study results: Capecitabine (CAP) combined with oxaliplatin (OX) and preoperative radiation (RT) in patients (pts) with locally advanced rectal cancer (LARC).

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2005 .

Use of epiregulin (EREG) and amphiregulin (AREG) gene expression to predict response to cetuximab (cet) in combination with oxaliplatin (Ox) and 5FU in the first-line treatment of advanced colorectal cancer (aCRC).

M. D. James, B. Jasani, J. Cheadle, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

University of Birmingham Investigating the poor outcomes of BRAF-mutant advanced colorectal cancer

P. Quirke, J. Cheadle, G. Middleton, 2017 .

Determining barriers to effective data sharing in cancer genomic sequencing initiatives: A Global Alliance for Genomics and Health (GA4GH) survey.

M. Caulfield, L. Esserman, M. Watson, 2016 .

Campath-1H treatment of T-cell prolymphocytic leukemia in patients for whom at least one prior chemotherapy regimen has failed.

B. Leber, P. Hérait, K. Rai, 2002, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Epirubicin, cisplatin and continuous infusion 5-fluorouracil (ECF) as neoadjuvant chemotherapy in gastro-oesophageal cancer.

A. Melcher, T. Maughan, D. Mort, 1996, British Journal of Cancer.

Endosonographic staging of 100 consecutive patients with esophageal carcinoma: introduction of the 8-mm esophagoprobe.

G. Williams, S. Roberts, P. Carey, 1999, Diseases of the esophagus : official journal of the International Society for Diseases of the Esophagus.

Phase II trials of flavone acetic acid in advanced malignant melanoma and colorectal carcinoma.

D. Kerr, G. Rustin, N. Bleehen, 1989, British Journal of Cancer.

Tumour concentrations of flavone acetic acid (FAA) in human melanoma: comparison with mouse data.

N. Bleehen, P. Workman, T. Maughan, 1992, British Journal of Cancer.

Oxaliplatin/capecitabine or carboplatin/paclitaxel-based preoperative chemoradiation for resectable oesophageal adenocarcinoma (NeoSCOPE): Long-term results of a randomised controlled trial

H. Grabsch, Ricky A. Sharma, T. Crosby, 2021, European journal of cancer.

A prospective comparison of multidisciplinary treatment of oesophageal cancer with curative intent in a UK cancer network.

T. Crosby, S. Roberts, W. Lewis, 2007, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

A proliferative subtype of colorectal liver metastases exhibits hypersensitivity to cytotoxic chemotherapy

R. Weichselbaum, M. Talamonti, M. D'Angelica, 2022, npj Precision Oncology.

A randomized clinical trial of chemotherapy compared to chemotherapy in combination with cetuximab in k-RAS wild-type patients with operable metastases from colorectal cancer: The new EPOC study.

T. Hickish, J. Gardner-Thorpe, D. Cunningham, 2013 .

The “Molecularly Unstratified” Patient: A Focus for Moral, Psycho-Social and Societal Research

R. Sullivan, T. Maughan, L. Morrell, 2017, Biomedicine Hub.

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts)

W. Scheithauer, H. Burris, J. Douillard, 2004 .

6097 POSTER Ciclosporin in Combination With Irinotecan for Chemoresistant Advanced Colorectal Cancer – Results of PICCOLO, a Large Randomised Trial With Prospective Molecular Stratification

S. Gwyther, G. Middleton, S. Richman, 2011 .

Identification of potentially responsive subsets when cetuximab is added to oxaliplatin-fluoropyrimidine chemotherapy (CT) in first-line advanced colorectal cancer (aCRC): Mature results of the MRC COIN trial.

J. Cheadle, T. Maughan, D. Fisher, 2010 .

Severe Prolonged Immunosuppression following Fludarabine and Rituximab Combination Therapy

J. Lester, E. Hudson, T. Maughan, 2008, Chemotherapy.

Adverse reactions to Campath-1H monoclonal antibody

T. Maughan, C. Poynton, D. Mort, 1993, The Lancet.

The Use of Derivatives of α-MSH for Targeting to Melanomas In Vivo

T. Maughan, C. G. Knight, D. Bard, 1992 .

Deciphering colorectal cancer genetics through multi-omic analysis of 100,204 cases and 154,587 controls of European and east Asian ancestries

Stephanie A. Bien, Anna C. Wu, Aung Ko Win, 2022, Nature Genetics.

Molecular selection of therapy in metastatic colorectal cancer: the FOCUS4 molecularly stratified RCT

R. Butler, J. Graham, P. Quirke, 2022, Efficacy and Mechanism Evaluation.

Perioperative chemotherapy with or without cetuximab in patients (pts) with resectable colorectal liver metastasis (CRLM): Mature analysis of overall survival (OS) in the New EPOC randomised controlled trial

T. Hickish, D. Cunningham, J. Bridgewater, 2017 .

Molecular phenotyping of colorectal neoplasia shows dynamic and adaptive cancer stem cell population admixture

P. Wirapati, P. Dunne, L. Trusolino, 2022, bioRxiv.

Germline and Somatic Genetic Variants in the p53 Pathway Interact to Affect Cancer Risk, Progression, and Drug Response

H. Carter, P. Pharoah, C. Turnbull, 2021, Cancer Research.

Approaches to the evaluation of rapidly evolving radiotherapy technologies

M. Parmar, C. Faivre-Finn, L. Billingham, 2012 .

Different strategies of sequential and combination chemotherapy for patients with poor prognosis advanced colorectal cancer (MRC FOCUS): a randomised controlled trial

Richard J Stephens, Mahesh KB Parmar, M. Parmar, 2007, The Lancet.

The clinical value of serum CA125 levels in ovarian cancer patients receiving platinum therapy.

M. Shelley, T. Maughan, M. Adams, 1987, European journal of cancer & clinical oncology.

A phase II open label, randomised study of ipilimumab with temozolomide versus temozolomide alone after surgery and chemoradiotherapy in patients with recently diagnosed glioblastoma: the Ipi-Glio trial protocol

P. Hoskin, C. Roberts, T. Maughan, 2020, BMC Cancer.

TET2 drives 5hmc marking of GATA6 and epigenetically defines pancreatic ductal adenocarcinoma transcriptional subtypes.

E. O’Neill, D. Vavoulis, C. Verrill, 2021, Gastroenterology.

The Promise and the Hype of ‘Personalised Medicine’

Tim Maughan, T. Maughan, 2017, The New bioethics : a multidisciplinary journal of biotechnology and the body.

The evolutionary landscape of colorectal tumorigenesis

Ville Mustonen, Andrea Sottoriva, Xiaowei Jiang, 2018, Nature Ecology & Evolution.

Molecular Taxonomy and Tumourigenesis of Colorectal Cancer.

T. Maughan, S. Biswas, D. Holyoake, 2016, Clinical oncology (Royal College of Radiologists (Great Britain)).

Variation at 2q35 (PNKD and TMBIM1) influences colorectal cancer risk and identifies a pleiotropic effect with inflammatory bowel disease

V. Salomaa, D. Kerr, L. Aaltonen, 2016, Human molecular genetics.

Somatic Profiling of the Epidermal Growth Factor Receptor Pathway in Tumors from Patients with Advanced Colorectal Cancer Treated with Chemotherapy ± Cetuximab

D. Lambrechts, M. D. James, B. Jasani, 2013, Clinical Cancer Research.

Phenotypic consequences of somatic mutations in the ataxia-telangiectasia mutated gene in non-small cell lung cancer

A. Ryan, T. Maughan, A. Weber, 2016, Oncotarget.

Mendelian randomisation implicates hyperlipidaemia as a risk factor for colorectal cancer

Aung Ko Win, V. Salomaa, D. Kerr, 2017, International journal of cancer.

Predicting response to epidermal growth factor receptor-targeted therapy in colorectal cancer

T. Maughan, R. Adams, 2007, Expert review of anticancer therapy.

Image-based consensus molecular subtype (imCMS) classification of colorectal cancer using deep learning

K. Sirinukunwattana, C. Hardy, U. McDermott, 2020, Gut.

Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Jens Rittscher, Clare Verrill, Susan Richman, 2019, bioRxiv.

Title: Image-based consensus molecular subtype classification (imCMS) of colorectal cancer using deep learning

Tomlinson, K. Sirinukunwattana, C. Hardy, 2019 .

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

Harpreet Wasan, Tamas Hickish, Ayman Madi, 2011, The Lancet. Oncology.

In-depth Clinical and Biological Exploration of DNA Damage Immune Response as a Biomarker for Oxaliplatin Use in Colorectal Cancer

M. Salto‐Tellez, U. McDermott, P. Johnston, 2020, Clinical Cancer Research.

The Interleukin 22 Pathway Interacts with Mutant KRAS to Promote Poor Prognosis in Colon Cancer

M. Delorenzi, F. Powrie, M. Friedrich, 2020, Clinical Cancer Research.

A metagene of NRF2 expression is a prognostic biomarker in all stage colorectal cancer

Chieh-Hsi Wu, C. Holmes, T. Maughan, 2019, bioRxiv.

Clinicopathological differences and survival outcomes with first-line therapy in patients with left-sided colon cancer and rectal cancer: Pooled analysis of 2879 patients from AGITG (MAX), COIN, FOCUS2, OPUS, CRYSTAL and COIN-B trials in the ARCAD database.

D. Sargent, C. Bokemeyer, E. Van Cutsem, 2018, European journal of cancer.

Prospective patient stratification into robust cancer‐cell intrinsic subtypes from colorectal cancer biopsies

Aideen C Roddy, J. Stewart, C. Hurt, 2018, The Journal of pathology.

Addition of cetuximab to oxaliplatin-based first-line combination chemotherapy for treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

D. Lambrechts, M. D. James, J. Bridgewater, 2011, The Lancet.

The prognostic utility of pre‐treatment neutrophil‐to‐lymphocyte‐ratio (NLR) in colorectal cancer: A systematic review and meta‐analysis

T. Maughan, Mate Naszai, Alina Kurjan, 2021, Cancer medicine.

A phase I/II study of oxaliplatin when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group (CCOG) study

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2005, British Journal of Cancer.

Prognostic significance of hypoxia inducible factor-1α and vascular endothelial growth factor expression in patients with diffuse large B-cell lymphoma treated with rituximab

S. Gerry, A. Casbard, T. Maughan, 2013, Leukemia & lymphoma.

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33

Jean-Baptiste Cazier, Harry Campbell, Albert Tenesa, 2010, Nature Genetics.

A phase I/II study of irinotecan when added to 5-fluorouracil and leucovorin and pelvic radiation in locally advanced rectal cancer: a Colorectal Clinical Oncology Group Study

R. Glynne-Jones, T. Maughan, D. Sebag‐Montefiore, 2007, British Journal of Cancer.

Chromosomal instability mediates immune exclusion and response to cytotoxic chemotherapy in colorectal liver metastases

R. Weichselbaum, M. Talamonti, M. D'Angelica, 2021, bioRxiv.

Common genetic variation and survival after colorectal cancer diagnosis: a genome-wide analysis.

H. Brenner, J. Chang-Claude, M. Hoffmeister, 2016, Carcinogenesis.

Role of the Oxidative DNA Damage Repair Gene OGG1 in Colorectal Tumorigenesis

V. Moskvina, P. Quirke, P. Propping, 2013 .

Role of the oxidative DNA damage repair gene OGG1 in colorectal tumorigenesis.

V. Moskvina, P. Quirke, P. Propping, 2013, Journal of the National Cancer Institute.

Exploiting differential Wnt target gene expression to generate a molecular biomarker for colorectal cancer stratification

I. Tomlinson, P. Dunne, S. Leedham, 2019, Gut.

Does anti-EGFR therapy improve outcome in advanced colorectal cancer? A systematic review and meta-analysis.

M. Parmar, T. Maughan, J. Tierney, 2012, Cancer treatment reviews.

Evaluating many treatments and biomarkers in oncology: a new design.

M. Parmar, A. Crook, L. Brown, 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer

Aung Ko Win, D. Kerr, J. Hopper, 2015, Scientific Reports.

Explorer A new GWAS and meta-analysis with 1000 Genomes imputation identifies novel risk variants for colorectal cancer

D. Kerr, J. Hopper, D. Conti, 2017 .

C. Tournigand, R. Labianca, J. Ajani, 2017, Annals of oncology : official journal of the European Society for Medical Oncology.

Investigating the poor outcomes of BRAF -mutant advanced colorectal cancer to develop practical treatment strategies

P. Quirke, J. Cheadle, G. Middleton, 2017 .

Toxicity associated with combination oxaliplatin plus fluoropyrimidine with or without cetuximab in the MRC COIN trial experience

R. Kaplan, T. Maughan, D. Fisher, 2009, British Journal of Cancer.

The treatment of patients with low tumour burden and/or slow growing disease.

T. Maughan, 2011, European journal of cancer.

HER2-HER3 Heterodimer Quantification by FRET-FLIM and Patient Subclass Analysis of the COIN Colorectal Trial

Borivoj Vojnovic, Tony Ng, Manuel Rodriguez-Justo, 2019, Journal of the National Cancer Institute.

Capecitabine Versus Active Monitoring in Stable or Responding Metastatic Colorectal Cancer After 16 Weeks of First-Line Therapy: Results of the Randomized FOCUS4-N Trial

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Evaluation of Continuous Tumor-Size–Based End Points as Surrogates for Overall Survival in Randomized Clinical Trials in Metastatic Colorectal Cancer

C. Tournigand, M. Buyse, C. Bokemeyer, 2019, JAMA network open.

TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts

I. Torrecilla, J. Fielden, K. Wiseman, 2020, Nature Communications.

Lack of an association between gallstone disease and bilirubin levels with risk of colorectal cancer: a Mendelian randomisation analysis

H. Brenner, J. Chang-Claude, M. Hoffmeister, 2021, British Journal of Cancer.

Modifiable pathways for colorectal cancer: a mendelian randomisation analysis

H. Brenner, J. Chang-Claude, M. Hoffmeister, 2019, The lancet. Gastroenterology & hepatology.

A Cancer Research UK multicenter randomized phase II study of induction chemotherapy followed by gemcitabine- or capecitabine-based chemoradiotherapy for locally advanced nonmetastatic pancreatic cancer

C. Hurt, J. Staffurth, J. Bridgewater, 2010 .

OP13. Economics of the MRC colorectal working party CR06 trial

T. Maughan, D. Cohen, J. Hale, 1997 .

A phase II study of capecitabine and oxaliplatin combination chemotherapy in patients with inoperable adenocarcinoma of the gall bladder or biliary tract

M. Highley, J. Graham, L. Wall, 2016, BMC Research Notes.

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis: the New EPOC randomised controlled trial.

T. Hickish, R. Butler, O. Garden, 2014, The Lancet. Oncology.

Primary cutaneous CD30+ T‐cell lymphoproliferative disorder following cardiac transplantation in a 15‐year‐old boy with Netherton's syndrome

A. Finlay, T. Maughan, R. Katugampola, 2005, The British journal of dermatology.

Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers

N G Burnet, R I Mackay, R. Plummer, 2011, British Journal of Cancer.

Induction oxaliplatin capecitabine followed by switch to carboplatin-paclitaxel based RT versus continuing oxaliplatin capecitabine RT in operable esophageal adenocarcinoma: Survival analysis of the randomized phase II neoscope trial.

H. Grabsch, C. Hurt, Ricky A. Sharma, 2020 .

Small cell oesophageal carcinoma: an institutional experience and review of the literature

T. Crosby, J. Lester, E. Hudson, 2007, British Journal of Cancer.

Incorporating oxygenation levels in analytical DNA-damage models—quantifying the oxygen fixation mechanism

M. Hill, T. Maughan, F. Van den Heuvel, 2021, Physics in medicine and biology.

Shanghai international consensus on diagnosis and comprehensive treatment of colorectal liver metastases (version 2019).

Yi Wang, J. Oh, A. Benson, 2020, European journal of surgical oncology : the journal of the European Society of Surgical Oncology and the British Association of Surgical Oncology.

The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns

T. Dickhaus, M. T. Hasan, E. Berns, 2013, Epigenetics.

Pattern Recognition Receptor Polymorphisms as Predictors of Oxaliplatin Benefit in Colorectal Cancer

R. Houlston, I. Tomlinson, V. Escott-Price, 2019, Journal of the National Cancer Institute.

Next Generation Radiotheranostics Promoting Precision Medicine.

B. Hadaschik, O. Sartor, M. Hofman, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

A genome-wide search for determinants of survival in 1926 patients with advanced colorectal cancer with follow-up in over 22,000 patients.

R. Houlston, S. Gallinger, P. Newcomb, 2021, European journal of cancer.

FRAGMATIC: A randomised phase III clinical trial investigating the effect of fragmin® added to standard therapy in patients with lung cancer

S. Noble, D. Cohen, G. Griffiths, 2009, BMC Cancer.

Analyses of 7,635 Patients with Colorectal Cancer Using Independent Training and Validation Cohorts Show That rs9929218 in CDH1 Is a Prognostic Marker of Survival

D. Kerr, I. Tomlinson, P. Newcomb, 2015, Clinical Cancer Research.

Meta-analysis of three genome-wide association studies identifies susceptibility loci for colorectal cancer at 1q41, 3q26.2, 12q13.13 and 20q13.33

E. Dermitzakis, D. Kerr, L. Aaltonen, 2010, Nature Genetics.

Fusobacterium nucleatum, rectal cancer and radiotherapy.

T. Maughan, E. Mann, Tim Maughan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Genome‐wide association study and meta‐analysis in Northern European populations replicate multiple colorectal cancer risk loci

Aung Ko Win, V. Salomaa, D. Kerr, 2017, International journal of cancer.

[18F]Fluoromisonidazole PET in rectal cancer

James M. Wilson, M. Partridge, T. Maughan, 2017, EJNMMI Research.

From Rosalind Franklin to Barack Obama: Data Sharing Challenges and Solutions in Genomics and Personalised Medicine

Mark Lawler, Tim Maughan, M. Lawler, 2017, The New bioethics : a multidisciplinary journal of biotechnology and the body.

Impact of K-ras status on the effects of EGFR-targeted monoclonal antibody (MAb) therapy in advanced colorectal cancer (ACRC): A systematic review and meta-analysis of randomized controlled trials (RCTs).

M. Parmar, T. Maughan, J. Tierney, 2009, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

The management of skin reactions in cancer patients receiving epidermal growth factor receptor targeted therapies

E. Van Cutsem, J. Tabernero, A. Santoro, 2005, Journal der Deutschen Dermatologischen Gesellschaft = Journal of the German Society of Dermatology : JDDG.

Pro-inflammatory fatty acid profile and colorectal cancer risk : A Mendelian randomisation analysis

Aung Ko Win, V. Salomaa, D. Kerr, 2017 .

Effectiveness of preoperative staging in rectal cancer: digital rectal examination, endoluminal ultrasound or magnetic resonance imaging?

R. Newcombe, M. Bourne, A. Radcliffe, 2004, British Journal of Cancer.

Design and Conduct of research and clinical trials

K. Hood, A. Byrne, T. Maughan, 2008 .

Association of age with survival in patients with metastatic colorectal cancer: analysis from the ARCAD Clinical Trials Program.

D. Sargent, R. Goldberg, L. Saltz, 2014, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

P. Hoskin, C. Roberts, T. Maughan, 2020, BMC Cancer.

LBA26 BREAKWATER safety lead-in (SLI): Encorafenib (E) + cetuximab (C) + chemotherapy (chemo) for BRAFV600E metastatic colorectal cancer (mCRC)

E. Van Cutsem, R. Yaeger, S. Kopetz, 2022, Annals of Oncology.

Intermittent versus continuous oxaliplatin-fluoropyrimidine (Ox-Fp) chemotherapy (CT) to first-line treatment of patients (pts) with advanced colorectal cancer (aCRC): Predictive factors (PF), quality of life (QL), and final efficacy results from the MRC COIN trial

J. Cassidy, T. Maughan, D. Fisher, 2010 .

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2-3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Irinotecan/fluorouracil combination in first-line therapy of older and younger patients with metastatic colorectal cancer: combined analysis of 2,691 patients in randomized controlled trials.

R. Stephens, E. Van Cutsem, L. Saltz, 2008, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Research-intensive cancer care in the NHS in the UK.

M. Parmar, D. Stewart, R. Wilson, 2011, Annals of oncology : official journal of the European Society for Medical Oncology.

Advanced Radiotherapy Technologies Network in the UK (ART-NET) - focus on lung cancer

D. Hawkes, F. V. Heuvel, K. Harrington, 2018 .

Systemic chemotherapy with or without cetuximab in patients with resectable colorectal liver metastasis (New EPOC): long-term results of a multicentre, randomised, controlled, phase 3 trial

T. Hickish, N. Heaton, O. Garden, 2020, The Lancet. Oncology.

NRF2 Mediates Therapeutic Resistance to Chemoradiation in Colorectal Cancer through a Metabolic Switch

Chieh-Hsi Wu, Rachael Thomas, T. Maughan, 2021, Antioxidants.

MErCuRIC1: A phase 1a study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in patients with advanced solid tumours

M. Salto‐Tellez, F. Nicolantonio, A. Bardelli, 2016 .

Abstract 1396: Validation of a MEK/MET-specific NGS panel for early phase trial interrogation

P. Maxwell, A. Bardelli, P. Laurent-Puig, 2016 .

Stromal composition predicts recurrence of early rectal cancer after local excision

D. Kerr, S. Leedham, H. Danielsen, 2021, Histopathology.

Personalizing Survival Predictions in Advanced Colorectal Cancer: The ARCAD Nomogram Project

C. Tournigand, D. Sargent, R. Simes, 2018, Journal of the National Cancer Institute.

A robust multiplex immunofluorescence and digital pathology workflow for the characterisation of the tumour immune microenvironment

M. Salto‐Tellez, P. Quirke, E. Domingo, 2020, Molecular oncology.

A feasibility study testing four hypotheses with phase II outcomes in advanced colorectal cancer (MRC FOCUS3): a model for randomised controlled trials in the era of personalised medicine?

M. Parmar, G. Taylor, R. Butler, 2014, British Journal of Cancer.

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.

J. Maynard, J. Cheadle, S. Idziaszczyk, 2018, European journal of cancer.

Germline variation in RASAL2 may predict survival in patients with RAS‐activated colorectal cancer

R. Houlston, V. Escott-Price, J. Cheadle, 2023, Genes, chromosomes & cancer.

Erratum: A new GWAS and meta-analysis with 1000Genomes imputation identifies novel risk variants for colorectal cancer

Aung Ko Win, D. Kerr, J. Hopper, 2015, Scientific Reports.

Inhibition of WEE1 Is Effective in TP53- and RAS-Mutant Metastatic Colorectal Cancer: A Randomized Trial (FOCUS4-C) Comparing Adavosertib (AZD1775) With Active Monitoring

M. Parmar, R. Butler, J. Graham, 2021, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

A randomised phase III trial of the pharmacokinetic biomodulation of irinotecan using oral ciclosporin in advanced colorectal cancer: results of the Panitumumab, Irinotecan & Ciclosporin in COLOrectal cancer therapy trial (PICCOLO).

S. Gwyther, J. Bridgewater, J. Wagstaff, 2013, European journal of cancer.

CA125 in ovarian tumour tissue at second laparotomy.

B. Jasani, G. Williams, M. Shelley, 1989, British Journal of Cancer.

Molecular biomarkers and precision medicine in colorectal cancer: a systematic review of health economic analyses

M. Lawler, R. Sullivan, M. Clarke, 2017, Oncotarget.

Exome Resequencing Identifies Potential Tumor‐Suppressor Genes that Predispose to Colorectal Cancer

Howard L McLeod, Richard Kaplan, M. Wagner, 2013, Human mutation.

Genome‐wide association studies of toxicity to oxaliplatin and fluoropyrimidine chemotherapy with or without cetuximab in 1800 patients with advanced colorectal cancer

R. Houlston, V. Escott-Price, J. Cheadle, 2021, International journal of cancer.

Marimastat as maintenance therapy for patients with advanced gastric cancer: a randomised trial

J. Scholefield, R. Hawkins, T. Maughan, 2002, British Journal of Cancer.

Derived neutrophil lymphocyte ratio is predictive of survival from intermittent therapy in advanced colorectal cancer: a post hoc analysis of the MRC COIN study

J. Bridgewater, T. Maughan, D. Fisher, 2016, British Journal of Cancer.

Estimation of plasma area under the curve for etanidazole (SR 2508) in toxicity prediction and dose adjustment.

N. Bleehen, P. Workman, T. Maughan, 1989, International journal of radiation oncology, biology, physics.

Pancreatic cancer within a UK cancer network with special emphasis on locally advanced non-metastatic pancreatic cancer.

E. Hudson, T. Maughan, S. Mukherjee, 2008, Clinical oncology (Royal College of Radiologists (Great Britain)).

Chemotherapy options in elderly and frail patients with metastatic colorectal cancer (MRC FOCUS2): an open-label, randomised factorial trial

M. Parmar, H. Wasan, G. Middleton, 2011, The Lancet.

Early predictors of prolonged overall survival (OS) in patients (pts) on first-line chemotherapy (CT) for metastatic colorectal cancer (mCRC): An ARCAD study with individual patient data (IPD) on 10,962 pts.

C. Tournigand, D. Sargent, M. Buyse, 2014 .

Circulating biomarkers and outcomes from a randomised phase 2 trial of gemcitabine versus capecitabine-based chemoradiotherapy for pancreatic cancer

C. Hurt, E. O’Neill, A. Abraham, 2020, British Journal of Cancer.

Abstract 3867: STAT1-related antigen processing and presentation dictates prognosis in the fibroblast-rich subtype of stage II/III colon cancer

P. Dunne, O. Sansom, M. Lawler, 2020 .

MErCuRIC1: A Phase I study of MEK1/2 inhibitor PD-0325901 with cMET inhibitor crizotinib in RASMT and RASWT (with aberrant c-MET) metastatic colorectal cancer (mCRC) patients.

M. Salto‐Tellez, F. Nicolantonio, A. Bardelli, 2015 .

Capecitabine (Cap) and oxaliplatin (Ox) in elderly and/or frail patients with metastatic colorectal cancer: The FOCUS2 trial

H. Wasan, T. Maughan, R. Langley, 2007 .

Patterns of progression, treatment of progressive disease and post-progression survival in the New EPOC study

T. Hickish, O. Garden, D. Cunningham, 2016, British Journal of Cancer.

sigQC: A procedural approach for standardising the evaluation of gene signatures

Jacob G. Scott, A. Harris, A. Dhawan, 2017, bioRxiv.

Safety of capecitabine (X) compared to fluorouracil/leucovorin (5-FU/LV) for the adjuvant treatment of elderly colon cancer patients (pts).

W. Scheithauer, H. Burris, J. Douillard, 2004, Journal of Clinical Oncology.

Guidelines for using sigQC for systematic evaluation of gene signatures

Jacob G. Scott, A. Harris, A. Dhawan, 2019, Nature Protocols.

Changing the Paradigm—Multistage Multiarm Randomized Trials and Stratified Cancer Medicine.

M. Lawler, T. Maughan, R. Kaplan, 2015, The oncologist.

The clinical impact of expert pathological review on lymphoma management: a regional experience

J. Lester, R. Attanoos, T. Maughan, 2003, British journal of haematology.

Long-term outcome from the SCALOP trial: a multi-centre randomized phase II trial of gemcitabine or capecitabine-based chemoradiation (CRT) for locally advanced pancreatic cancer (LAPC)

R. Abrams, C. Hurt, J. Staffurth, 2016 .

Efficacy of early PET-CT directed switch to carboplatin and paclitaxel based definitive chemoradiotherapy in patients with oesophageal cancer who have a poor early response to induction cisplatin and capecitabine in the UK: a multi-centre randomised controlled phase II trial

E. Spezi, K. Bradley, T. Crosby, 2023, EClinicalMedicine.

Mendelian randomisation analysis strongly implicates adiposity with risk of developing colorectal cancer

Aung Ko Win, V. Salomaa, D. Kerr, 2016, British Journal of Cancer.

K. Fisher, T. Maughan, D. Sebag‐Montefiore, 2020, Radiation oncology.

Relationship between 233 colorectal cancer risk loci and survival in 1926 patients with advanced disease

R. Houlston, V. Escott-Price, J. Cheadle, 2023, BJC Reports.

Portfolio learning with cancer patients: an integrated module in undergraduate medical education.

I. Finlay, T. Maughan, D. Webster, 2001, Clinical oncology (Royal College of Radiologists (Great Britain)).

FOCUS 3: A study to determine the feasibility of molecular selection of therapy using K-RAS, B-RAF, and topo-1 in patients with advanced colorectal cancer (ACRC).

M. Parmar, Geraint T. Williams, R. Butler, 2012, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Prognostic and Predictive Impact of Primary Tumor Sidedness for Previously Untreated Advanced Colorectal Cancer.

C. Bokemeyer, E. Van Cutsem, C. Punt, 2021, Journal of the National Cancer Institute.

A prospective phase II study of pre-operative chemotherapy then short-course radiotherapy for high risk rectal cancer: COPERNICUS

C. Hurt, P. Quirke, G. Griffiths, 2018, British Journal of Cancer.

Costs and consequences of different chemotherapy regimens in metastatic colorectal cancer

R. Stephens, T. Maughan, D. R. Cohen, 2002, British Journal of Cancer.

Polychemotherapy in advanced non-small-cell lung cancer

A. Rodger, P. Souquet, T. Maughan, 1993, The Lancet.

Integrated Clinical-Molecular Classification of Colorectal Liver Metastases: A Biomarker Analysis of the Phase 3 New EPOC Randomized Clinical Trial.

R. Weichselbaum, M. Talamonti, M. Posner, 2023, JAMA oncology.

The impact of young age on survival in patients with metastatic colorectal cancer: Analysis from the ARCAD Clinical Trials Program

D. Sargent, R. Goldberg, L. Saltz, 2013 .

The polymorphic variant rs1800734 influences methylation acquisition and allele-specific TFAP4 binding in the MLH1 promoter leading to differential mRNA expression

I. Tomlinson, M. Tomková, S. Kriaucionis, 2019, Scientific Reports.

Exploring the poor outcomes of BRAF mutant (BRAF mut) advanced colorectal cancer (aCRC): Analysis from 2,530 patients (pts) in randomized clinical trials (RCTs).

R. Butler, P. Quirke, J. Cheadle, 2015 .

Comparison of intermittent and continuous palliative chemotherapy for advanced colorectal cancer: a multicentre randomised trial

D. Kerr, C. McArdle, R. Stephens, 2003, The Lancet.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial.

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF, PIK3CA, KRAS, and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2017, The lancet. Gastroenterology & hepatology.

Inhibition of EGFR, HER2, and HER3 signalling in patients with colorectal cancer wild-type for BRAF , PIK3CA , KRAS , and NRAS (FOCUS4-D): a phase 2–3 randomised trial

R. Butler, P. Quirke, H. Wasan, 2018 .

Association analyses identify 31 new risk loci for colorectal cancer susceptibility

K. D. Sørensen, Aung Ko Win, I. Deary, 2019, Nature Communications.

Pro-inflammatory fatty acid profile and colorectal cancer risk: A Mendelian randomisation analysis

Aung Ko Win, V. Salomaa, L. Aaltonen, 2017, European journal of cancer.

Fluoropyrimidine-induced hand-foot syndrome and cardiotoxicity: recommendations for the use of the oral fluoropyrimidine S-1 in metastatic colorectal cancer

E. Van Cutsem, V. Heinemann, G. Bodoky, 2023, ESMO open.

C. Hurt, E. O’Neill, J. Bridgewater, 2019, BMC Cancer.

Abstract PR02: Loss of TET2 activity results in epigenetic instability and drives PDAC molecular subtypes

E. O’Neill, A. Abraham, A. Schuh, 2019 .

Depletion of signal recognition particle 72kDa increases radiosensitivity

W. Mckenna, F. Buffa, T. Maughan, 2017, Cancer biology & therapy.

Cancer-cell intrinsic gene expression signatures minimise the confounding effects of intratumoural heterogeneity in colorectal cancer patient classification

Aideen C Roddy, P. Johnston, D. Longley, 2017 .

NEOSCOPE: A randomised Phase II study of induction chemotherapy followed by either oxaliplatin/capecitabine (OXCAP) or carboplatin/paclitaxel (CarPac) based chemoradiation (CRT) as pre-operative regimen for resectable oesophageal adenocarcinoma

H. Grabsch, C. Hurt, Ricky A. Sharma, 2016 .

TEX264 coordinates p97- and SPRTN-mediated resolution of topoisomerase 1-DNA adducts

I. Torrecilla, J. Fielden, K. Wiseman, 2020, Nature Communications.

Intermittent versus continuous oxaliplatin and fluoropyrimidine combination chemotherapy for first-line treatment of advanced colorectal cancer: results of the randomised phase 3 MRC COIN trial

T. Hickish, H. Wasan, T. Maughan, 2011, The Lancet. Oncology.

Edinburgh Research Explorer Modifiable pathways for colorectal cancer: A Mendelian randomisation analysis

S. Farrington, T. Maughan, A. Cornish, 2019 .

Chemotherapy-free intervals for patients with metastatic colorectal cancer remain an option.

T. Maughan, R. Kaplan, M. Seymour, 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

ADDITION OF CETUXIMAB TO OXALIPLATIN-BASED COMBINATION CHEMOTHERAPY (CT) IN PATIENTS WITH K-ras WILD-TYPE ADVANCED COLORECTAL CANCER (ACRC): EFFECTS ON OVERALL SURVIVAL. MRC COIN (CR10) TRIAL RESULTS

B. Jasani, J. Cheadle, H. Wasan, 2009 .

Methodological considerations in the evaluation of radiotherapy technologies.

R. Mackay, L. Billingham, J. Staffurth, 2012, Clinical oncology (Royal College of Radiologists (Great Britain)).

ESMO consensus guidelines for the management of patients with metastatic colorectal cancer.

W. Oyen, R. Labianca, W. Scheithauer, 2016, Annals of oncology : official journal of the European Society for Medical Oncology.

Radiotherapy research priorities for the UK.

R. Plummer, K. Harrington, R. Mackay, 2010, Clinical oncology (Royal College of Radiologists (Great Britain)).

Mismatch Repair Status and BRAF Mutation Status in Metastatic Colorectal Cancer Patients: A Pooled Analysis of the CAIRO, CAIRO2, COIN, and FOCUS Studies

I. Nagtegaal, B. Ylstra, G. Meijer, 2014, Clinical Cancer Research.

C. Tournigand, D. Sargent, C. Punt, 2016, The Lancet. Oncology.

Correlating Tumour Histology and ex vivo MRI Using Dense Modality-Independent Patch-Based Descriptors

Julia A. Schnabel, Bartlomiej W. Papiez, James M. Wilson, 2015, Patch-MI@MICCAI.

Prognostic value of liver metastases in colorectal cancer treated by systemic therapy: An ARCAD pooled analysis.

E. Van Cutsem, C. Punt, J. Tabernero, 2023, Journal of Clinical Oncology.

Pre-trial inter-laboratory analytical validation of the FOCUS4 personalised therapy trial

M. D. James, R. Butler, P. Quirke, 2015, Journal of Clinical Pathology.

Pharmacogenetic analyses of 2183 patients with advanced colorectal cancer; potential role for common dihydropyrimidine dehydrogenase variants in toxicity to chemotherapy.

J. Maynard, J. Cheadle, S. Idziaszczyk, 2018, European journal of cancer.

Cetuximab combined with infusional 5-fluorouracil/folinic acid (5-FU/FA) and oxaliplatin in metastatic colorectal cancer (mCRC): A pooled analysis of COIN and OPUS study data.

C. Bokemeyer, J. Tabernero, G. Folprecht, 2012 .

SCALOP: Results of a randomized phase II study of induction chemotherapy followed by gemcitabine (G) or capecitabine (Cap) based chemoradiation (CRT) in locally advanced pancreatic cancer (LANPC).

R. Abrams, C. Hurt, J. Staffurth, 2013 .